CASI Pharmaceuticals (CASIF) Equity Average (2021 - 2024)

CASI Pharmaceuticals (CASIF) reported Equity Average of $4.5 billion for Q2 2024, up 22700.94% quarter-over-quarter from $19.8 million in Q1 2024.

CASI Pharmaceuticals (CASIF) Equity Average (2021 - 2024) Analysis & Trends

CASI Pharmaceuticals has reported Equity Average for 2 years, with the latest figure at $4.5 billion in Q2 2024.

For the quarter ending Q2 2024, Equity Average changed N/A year-over-year to $4.5 billion; the trailing twelve-month figure through Jun 2024 stood at $4.5 billion (changed N/A YoY), and the FY2025 full-year result was -$17.7 million, down 236.19% from the prior year.
Equity Average for Q2 2024 stood at $4.5 billion, up from $19.8 million in the prior quarter.
The five-year high for Equity Average was $4.5 billion in Q2 2024, with the low at $19.8 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Avg. (Qtr)
1	Alterity Therapeutics	860,679.92 Bn	860,679.89 Bn	-	3.50 Bn
2	Belite Bio	55,284.00 Bn	55,284.00 Bn	-	783.14 Mn
3	Quantum Biopharma	16,206.94 Bn	16,206.93 Bn	-	3.76 Mn
4	Legend Biotech	3,318.00 Bn	3,317.71 Bn	242.10 Mn	1.01 Bn
5	Akari Therapeutics	1,543.84 Bn	1,543.84 Bn	-	21.35 Mn
6	Evaxion A	1,449.11 Bn	1,449.09 Bn	-	-
7	Psyence Biomedical	216.99 Bn	216.98 Bn	-	-
8	Vertex Pharmaceuticals	115.22 Bn	107.97 Bn	2.59 Bn	19.01 Bn
9	Abivax	90.58 Bn	90.58 Bn	-	516.41 Mn
10	CASI Pharmaceuticals	-	-	3.69 Mn	-

Download Data